首页> 外文期刊>Progress in Neuro-Psychopharmacology & Biological Psychiatry: An International Research, Review and News Journal >Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients.
【24h】

Platelet MAO activity during treatment with pegylated interferon-alfa in melanoma patients.

机译:聚乙二醇干扰素-α治疗黑色素瘤患者的血小板MAO活性。

获取原文
获取原文并翻译 | 示例
           

摘要

Depression and cognitive disturbance are well-known neuropsychiatric side effects of therapy with interferon-alfa (IFN-alfa). Aggression and irritability are also reported as side effects. Probably, central nervous system (CNS) serotonergic dysfunction is one of the underlying pathophysiological mechanisms of IFN-alfa-induced neuropsychiatric toxicity. Platelet activity of monoamine oxidase-B (MAO; EC1.4.3.4) is a possible indicator of central serotonergic function. Moreover, low platelet MAO activity is linked to impulsiveness, addiction and personality disorder. In this exploratory study in 17 high-risk melanoma patients, platelet counts, whole blood MAO, and platelet MAO activity were measured before and during therapy with IFN-alfa. Patients were randomized to treatment either with pegylated IFN-alfa (PEG-IFN-alfa) once a week at a dose of 6 mug/kg/week subcuteanously (s.c.) during 8 weeks, followed by a maintenance treatment of 3 mug/kg/week s.c. for a total of 5 years, or to observation only. Blood samples were taken at baseline, 4 and 8 weeks and 3 months. During treatment with IFN-alfa, platelet counts decreased at 4 and 8 weeks and 3 months, while platelet MAO activity increased, both compared to baseline and compared to non-treated controls. Compared to non-treated controls, platelet MAO activity increased with 86.4% (95 CI: 52.9-127.2). No significant changes in platelet MAO activity were observed in the control group. This indicates that platelet MAO activity is influenced by IFN-alfa. Since platelet MAO activity is a model for CNS MAO-B activity, it may be speculated that CNS MAO-B activity will also be increased. This could influence serotonin (5-HT) metabolism and thereby contribute to the development of psychiatric disturbance. However, a preferential inhibition of platelet production cannot be ruled out. Hypothetically, the antiproliferative effects of IFN-alfa could interfere more strongly with the synthesis of platelets than with the synthesis of mitochondria. In that case, increased platelet MAO activity reflects an increased number of mitochondria per platelet.
机译:抑郁和认知障碍是干扰素-α(IFN-alfa)治疗的众所周知的神经精神副作用。侵略性和易怒性也被报道为副作用。中枢神经系统(CNS)的血清素能功能障碍可能是IFN-α诱导的神经精神毒性的潜在病理生理机制之一。单胺氧化酶-B(MAO; EC1.4.3.4)的血小板活性可能是中央血清素能功能的指标。此外,低血小板MAO活性与冲动,成瘾和人格障碍有关。在这项针对17名高危黑色素瘤患者的探索性研究中,在用IFN-α治疗之前和治疗期间测量了血小板计数,全血MAO和血小板MAO活性。患者随机接受聚乙二醇化干扰素-α(PEG-IFN-alfa)治疗,每周一次,皮下注射6杯/千克/周,皮下注射(sc)8周,然后维持治疗3杯/千克/周SC总共5年,或仅用于观察。在基线,4、8周和3个月时采集血样。与基线和与未治疗的对照组相比,在用IFN-α治疗期间,血小板计数在第4、8周和3个月减少,而血小板MAO活性增加。与未治疗的对照组相比,血小板MAO活性增加了86.4%(95 CI:52.9-127.2)。在对照组中未观察到血小板MAO活性的显着变化。这表明血小板MAO活性受IFN-α影响。由于血小板MAO活性是CNS MAO-B活性的模型,因此可以推测CNS MAO-B活性也将增加。这可能会影响5-羟色胺(5-HT)的代谢,从而促进精神障碍的发展。然而,不能排除对血小板产生的优先抑制。假设地,IFN-α的抗增殖作用可能比线粒体的合成更强烈地干扰血小板的合成。在这种情况下,血小板MAO活性的增加反映了每个血小板线粒体数量的增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号